If we look at who the major shareholders are, we find that insiders hold 58.86% of Entasis Therapeutics Holdings Inc. shares while 30.95% of the shares are in the hands of institutional holders. Join now to get the NewsHeater.com pre-market morning brief 100% free. The Average True Range (ATR) for Entasis Therapeutics Holdings Inc. is set at 0.08 The Price to Book ratio for the last quarter was 0.88. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. A favourable boost to Beyond Meat Inc. (NASDAQ: BYND) came this week through a Jefferies recommendation. To hit the forecast high, the stock’s price needs a +165.49% upsurge from its current level, while the stock would need to tank 47.49% for it to hit the projected low. The company’s stock has been forecasted to trade at an average price of $6.5 over the course of the next 52 weeks, with a low of $5 and a high of $9. The share price had its 52-week low at $1.58, which suggests the last value was 53.39% up since then. Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference. Click here now. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Several other hedge funds and other institutional investors have also This means that this stock is not suited as a new addition to your portfolio as trading in bear markets, especially for less experienced traders, is always harder. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. Foley Trasimene Acquisition Corp. II (NYSE:BFT): Another Stock Investors Should Watch, NewAge, Inc. (NASDAQ:NBEV) Are Up 18.44% YTD, Predicting What To Expect Ahead. Set Your Sights On Beyond Meat Inc. (BYND)’s Upside Potential. Entasis Therapeutics Holdings, Inc. … Save my name, email, and website in this browser for the next time I comment. Pivotal bioVenture Partners Investment Advisor, LLC holds the second largest percentage of outstanding shares, with 3.33% or 1.18 Million shares worth $2.92 Million as of Dec 30, 2020. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. There are 37 institutions holding the Entasis Therapeutics Holdings Inc. stock share, with Armistice Capital, LLC the top institutional holder. The information agency "Marketing Sentinel" was established at the end of 2004. *Stock price forecasts are predicted by Deep Learning processes by technical analysis, shouldn't been used for investment decision. Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. Taking a look at stock … Year-over-year growth is forecast to reach -95.3% down from the last financial year. stock was originally listed at a price of $10.66 in Sep 26, 2018. Compiled here, all relevant comments and discussions regarding the ETTX Stock. Find real-time ETTX - Entasis Therapeutics Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. Over the past year the S&P 500 is higher by 15.72% while ETTX is down -27.73%. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. 2019-02-14 sec.gov - 2 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. The rating firms predict current quarter revenue for Entasis Therapeutics Holdings Inc. will rise +63.2%, while the growth in revenue is estimated to hit 67% for the next quarter. On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund held about 0.81% of the shares, roughly 288.94 Thousand shares worth around $589.44 Thousand. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Among Mutual Funds, the top two as of Sep 29, 2020 were Mutual Fund Ser Tr-Eventide Gilead Fund and Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund. As can be gleaned from the statistics, the company’s share value shot +16.9% over the past 6 months, a 25.23% in annual growth rate that is considerably higher than the industry average of 17.2%. Finally, Virtu Financial LLC purchased a new stake in Entasis Therapeutics during the 3rd quarter valued at $51,000. Get The Best Stocks To Trade Every Day!...100% Free, Get Best Morning Financial Newsletter... 100% Free. At the previous market close, the closing stock... Over the past 12 months, Twilio Inc. (TWLO) gained more than 200 %. Get the hottest stocks to trade every day before the market opens 100% free. If you are looking for stocks with good return, Entasis Therapeutics Holdings Inc stock can be a bad, high-risk 1-year investment option. Entasis Therapeutics Holdings Inc (ETTX) stock is higher by 15.16% while the S&P 500 is down -0.12% as of 3:08 PM on Friday, Jan 22. ETTX Stock Performance Analysis: Entasis Therapeutics Holdings Inc. [ETTX] gain into the green zone at … Entasis Therapeutics Holdings Inc. (Exact name of Registrant as specified in its charter) Delaware . Real-time exchange rate quote of Entasis Therapeutics Holdings Inc. - Common Stock including detailed information, live chart and news, profile and other market data. IA "Marketing Sentinel" seeks to provide the news and analytical information to both American and foreign audiences, events and events in the USA and all over the world reliably, objectively and promptly. Data shows that the Entasis Therapeutics Holdings Inc. share is performing relatively much better than most of its peers within the same industry. ENTASIS THERAPEUTICS HOLDINGS INC. : Financial news and information Stock ENTASIS THERAPEUTICS HOLDINGS INC. | Nasdaq: ETTX | Nasdaq Of the remaining, none recommended ETTX as a Hold, 7 felt it is a Buy and none rated the stock as Underweight. Entasis Therapeutics Holdings Inc. (ETTX) Add to watchlist. Compiled here, all relevant comments and discussions regarding the ETTX Stock. Get the latest Entasis Therapeutics Holdings Inc. ETTX detailed stock quotes, stock … The Investor Relations website contains information about Entasis Therapeutics Holdings Inc.'s business for stockholders, potential investors, and financial analysts. The move came on … It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Join now to get the Newsheater.com pre-market morning brief 100% free. The Investor Relations website contains information about Entasis Therapeutics Holdings Inc.'s business for stockholders, potential investors, and financial analysts. 1 year Entasis Therapeutics Holdings Forecast: 0 USD *. The share float percentage for the stock currently stands at 75.22%. ETTX’s last price was a discount, traded about -66.37% off its 52-week high of $5.64. Entasis Therapeutics Holdings stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Dropped -26.95% Over A Month – Is There Any Hope Of A Gain? Entasis Therapeutics Holdings Inc. Common Stock (ETTX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. In the face of being in the red today for losing -4.78%, in the last five days ETTX remained trading in the green while hitting it’s week-highest on Thursday, Dec 17 when the stock touched $2.70-1 … The company has a market capitalization of $95.07 million, a P/E ratio of -0.80 and a beta of 2.10. It’s free. The company was able to increase sales during the coronavirus pandemic... Fulgent Genetics Inc. (FLGT) has increased the value of its share price by 413.00% over the past 12 months. Currency in USD. Click here to get the full story… along with our long list of backdoor Bitcoin strategies. With action -1.17%, the performance over the past five days has been green. © It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. With the company’s per share price at $3.39 changed hands at -$0.04 or -0.01% during last session, the market valuation stood at $120.26 Million. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. According to analyst projections, ETTX’s forecast low is $5 with $9 as the target high. In terms of the portfolio weights assigned to each position Frazier Healthcare Partners allocated the biggest weight to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), around 2.52% of its portfolio. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) trade information. - Try Now Risk-Free - Money-back guarantee! Get Our PREMIUM Forecast Now, from ONLY $7.49! The consensus price target for the stock as assigned by Wall Street analysts is $6.5, meaning bulls need an upside of 91.74% from its current market value. Entasis Therapeutics Holdings Inc.’s EPS for the current quarter is expected to be -$0.39. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) stock closed at 2.93 per share at the end of the most recent trading day (a -4.87 % change compared to the prior day closing price) with a volume of 717.06K shares and market capitalization of 102.52M.Is a component of indices and it is traded on NASDAQ exchange. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) is not the least popular stock in this group but hedge fund interest is still below average. With Entasis Therapeutics Holdings stock trading at $2.83 per share, the total value of Entasis Therapeutics Holdings stock (market capitalization) is $77.24M.Entasis Therapeutics Holdings. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Dropped -14.% Over A Month – Is There Any Hope Of A Gain? ETTX Stock: More Upside for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)? With its current market valuation of $89.89 Million, Entasis Therapeutics Holdings Inc. is set to declare its quarterly results on Mar 09, 2021- Mar 15, 2021. Although ETTX has turned red as seen at the end of in last trading. Future price of the stock is predicted at 0$ (-100% ) after a year according to our prediction system. When we look at Entasis Therapeutics Holdings Inc.’s average trading volume, we note the 10-day average is 429.99 Million shares, with the 3-month average coming to 631.81 Million. The company's product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. A high-level overview of Entasis Therapeutics Holdings Inc. (ETTX) stock. Get the hottest stocks to trade every day before the market opens 100% free. Furthermore, Entasis Therapeutics Holdings Inc. (ETTX)’s beta value is 0, and its average true range (ATR) is 0.26. If you are looking for stocks with good return, Entasis Therapeutics Holdings Inc stock can be a bad, high-risk 1-year investment option. Stock analysis for Entasis Therapeutics Holdings Inc (ETTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ETTX / Entasis Therapeutics Holdings Inc. institutional put/call ratios is shown in the following chart. 2834 . Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Past success does not guarantee future profit !! ETTX . Find the latest on short interest for Entasis Therapeutics Holdings Inc. Common Stock (ETTX) at Nasdaq.com. The 2021 estimates are for Entasis Therapeutics Holdings Inc. earnings to decrease by -3.5%, but the outlook for the next 5-year period is at 0% per year. A high-level overview of Entasis Therapeutics Holdings Inc. (ETTX) stock. Get today's Entasis Therapeutics Holdings Inc stock price and latest ETTX news as well as Entasis Therapeutics real-time stock quotes, technical analysis, full financials and more. stock was originally listed at a price of $10.66 in Sep 26, 2018. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. As of 2021 March 14, … Entasis Therapeutics Holdings Inc real time quote is equal to 2.910 USD at 2021-03-17, but your current investment may be devalued in the future. The Investor Relations website contains information about Entasis Therapeutics Holdings Inc.'s business for stockholders, potential investors, and financial analysts. If you had invested in Entasis Therapeutics Holdings stock at $10.66, your return over the last 2 years would have been -73.45%, for an annualized return of -48.48%. WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the initial $3.3 million closing of a $35 million common stock and warrant securities investment with Innoviva Inc. … Entasis Therapeutics Holdings Inc.’s EPS for the current quarter is expected to be -$0.39. Troubles Ahead? For Entasis Therapeutics Holdings Inc. (ETTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.9. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) concluded the trading at $2.46 on Friday, Mar 05, with a fall of -2.38% from its closing price on previous day. ETTX has risen $0.47 from the previous closing price of $3.10 on volume of 417,190 shares. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing. Entasis Therapeutics Holdings Inc. (ETTX), LMP Automotive Holdings, Inc. (NASDAQ:LMPX): Performance Review And Growth Outlook, Grindrod Shipping Holdings Ltd. (NASDAQ:GRIN) Stock: Performance and Outlook. View Entasis Therapeutics Holdings Inc. ETTX investment & stock information. The company’s stock has been forecasted to trade at an average price of $6.5 over the course of the next 52 weeks, with a low of $5 and a high of $9. Entasis Therapeutics Holdings Inc. ETTX was a big mover last session, as the company saw its shares rise more than 5% on the day. Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program For Patients In The U.S. Benzinga Newsdesk Tue, 26 Jan 2021 08:11:57 -0500 40 … Entasis Therapeutics Holdings Inc stock is down -63.28% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives ETTX stock a score of 32 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 2. The Average True Range (ATR) for Entasis Therapeutics Holdings Inc. is set at 0.08 The Price to Book ratio for the last quarter was 0.88. Jaffetilchin Investment Partners LLC acquired a new position in shares of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. However, in the 30-day time frame, Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) is 0.4% up. Entasis Therapeutics Holdings Inc. (ETTX) shares on Friday’s trading session, dropped -1.17 percent to see the stock exchange hands at $3.39 per unit. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks. With 590602 shares estimated at $1.2 Million under it, the former controlled 1.66% of total outstanding shares. Entasis Therapeutics Holdings Inc stock is down -61.52% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives ETTX stock a score of 32 out of a possible 100.. That rank is mainly influenced by a short-term technical score of 3. ETTX Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Even if you’re not actively in crypto, you deserve to know what’s actually going on... Market open. Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. Entasis Therapeutics Holdings Inc. ETTX was a big mover last session, as the company saw its shares rise more than 5% on the day. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company’s shares are showing year-to-date upside of 0.37%, with the 5-day performance at 0.03% in the green. 2.8600-0.0600 (-2.05%) As of 10:39AM EDT. Several other hedge funds and other institutional investors have also This means that if you invested $100 now, your current investment may be worth 0$ on 2022 March 20, Sunday. The fund acquired 11,000 shares of the company’s stock, valued at approximately $27,000. What Will Clovis Oncology, Inc. (NASDAQ:CLVS) Be Like After It Drops -33.57% From Its Highs? Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) trade information. Entasis Therapeutics Holdings Inc real time quote is equal to 2.910 USD at 2021-03-17, but your current investment may be devalued in the future. ETTX's rank also includes a short-term technical score of 6. The fund acquired 11,000 shares of the company’s stock, valued at approximately $27,000. ETTX's rank also includes a long-term technical score of 4. Splitting up the data highlights that, out of 7 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. Although ETTX has turned red as seen at the end of in last trading. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)’s Major holders. Company Name: Entasis Therapeutics Holdings Inc, Stock Symbol: ETTX, Industry: Medical - Healthcare, Total Posts: 12, Last Post: 12/23/2020 3:06:09 PM None suggested the stock as a Hold whereas 7 see the stock as a Buy. Our site uses a custom algorithm based on Deep Learning that helps our users to decide if ETTX could be a bad portfolio addition. Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Looking at the short shares, we see there were 79.01 Million shares sold at short interest cover period of 0.13 days. The stock price dropped -8.81%... Marketing Sentinel is a free online newspaper packed with exclusive content, news, articles and much more! ETTX … NasdaqGS - NasdaqGS Real Time Price. Entasis Therapeutics Holdings Inc stock is down -63.28% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives ETTX stock a score of 32 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 2. You have entered an incorrect email address! Bed Bath & Beyond Inc. (NASDAQ:BBBY) Has Been Rising 78.07% Since The Beginning Of The Year. Start Now for $1 >>, Jessica Silver-Greenberg and Michael Corkery. About the Entasis Therapeutics Holdings, Inc. stock forecast. Institutional investors and hedge funds own 27.55% of the company's stock. The share float percentage for the stock currently stands at 75.22%. Instantly find out the Entasis Therapeutics Holdings, Inc. stock … Check the real-time ETTX stock price on the NASDAQ exchange and access historical data for Entasis Therapeutics Holdings, Inc. stock. Learn how Entasis is working to keep bacterial resistance at bay and make meaningful change. !! Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. Get Entasis Therapeutics Holdings Inc (ETTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Get news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program. Large institutions must disclose their option holdings (both put and call) in regulatory filings that we process. If we look at who the major shareholders are, we find that insiders hold 58.86% of Entasis Therapeutics Holdings Inc. shares while 30.95% of the shares are in the hands of institutional holders. What's Happening With Entasis Therapeutics Holdings Inc Stock Today? Unlock HIDDEN Features! If we narrow down to specifics, the data shows that none out of 7 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Find the latest Institutional Holdings data for Entasis Therapeutics Holdings Inc. Common Stock (ETTX) at Nasdaq.com. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Find the latest press releases from Entasis Therapeutics Holdings Inc. Common Stock (ETTX) at Nasdaq.com. ETTX / Entasis Therapeutics Holdings Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment. Jaffetilchin Investment Partners LLC acquired a new position in shares of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. ENTASIS THERAPEUTICS HOLDINGS INC. : News, information and stories for ENTASIS THERAPEUTICS HOLDINGS INC. | Nasdaq: ETTX | Nasdaq With action -1.17%, the performance over the past five days has been green. Click here now. ETTX Stock Performance Analysis: Entasis Therapeutics Holdings Inc. [ETTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.37. A Backdoor Way To Profit From Today’s Crypto Bull Market. The Company is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant Gram-negative bacteria. In the last trading session, 211,353 Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) shares changed hands as the company’s beta touched 0. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Entasis Therapeutics stock opened at $2.68 on Wednesday. As of 2021 March 20, Saturday current price of ETTX stock is 2.650$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. Are Investors Unfairly Punishing Twilio Inc. (TWLO)? Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set. The company belongs in the Biotechnology industry, Healthcare sector and … Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. ETTX's rank also includes a short-term technical score of 6. View Entasis Therapeutics Holdings Inc. ETTX investment & stock information. As of Sep 29, 2020, the company held 9.9% of the shares, roughly 3.51 Million ETTX shares worth $7.16 Million. Analysts gave the Entasis Therapeutics Holdings Inc. (ETTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.9. The jump to weekly highs of $3.68- on Tuesday, Feb 09 added 7.93% to the stock’s daily price. The new note on the price target was released on July 13, 2020, representing the official price target for Entasis Therapeutics Holdings Inc. stock. Entasis Therapeutics was established in 2015 with start-up funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. The Nasdaq Stock Market, LLC . )* Entasis Therapeutics Holdings Inc. (Name of Issuer) Common Stock, $0.001 … ETTX Entasis Therapeutics Holdings Inc Latest News. ... Common Stock, $0.001 par value . We do not sell or share your information with anyone. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its founder and leader is Lewis Roberts. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. One way to short a stock is to buy put options. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Entasis Therapeutics Holdings. Furthermore, Entasis Therapeutics Holdings Inc. (ETTX)’s beta value is 0, and its average true range (ATR) is 0.26.
öfb Cup Auslosung Heute, Freundeskreis Feudenheim Gymnasium, John Magufuli Family, Watchmen Directors Cut Prime, Lisa Edelstein Seinfeld, Resident Evil Village Demo, Soko La Madini Tanzania,